For decades, the wound care industry has directed the majority of its innovation investment towards treatment modalities, including advanced moist wound healing dressings, negative pressure wound therapy (NPWT), antimicrobial and biofilm-disrupting technologies, sophisticated exudate management systems, cellular and tissue-based products (CTPs), and, more recently, structured prevention programmes for pressure injuries and diabetic foot ulcers (DFUs). These advances have delivered meaningful improvements in patient outcomes while creating substantial commercial value.

Yet one of the most fundamental steps in the wound care pathway - accurate, timely, and reproducible diagnosis and assessment - continues to rely heavily on subjective clinical judgement. This imbalance represents one of the most significant untapped opportunities in advanced wound care today. For many of the leading platforms, the primary challenge is shifting from technological innovation to clinical integration and adoption.

The Cost of Diagnostic Variability

Most wound assessments still begin